Charles River Laboratories International, Inc. (CRL)

US — Healthcare Sector
Peers: IQV  MTD  TWST  WAT  ICLR  TECH  COO  BIO 

Automate Your Wheel Strategy on CRL

With Tiblio's Option Bot, you can configure your own wheel strategy including CRL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol CRL
  • Rev/Share 81.9674
  • Book/Share 69.169
  • PB 2.3228
  • Debt/Equity 0.8308
  • CurrentRatio 1.3604
  • ROIC 0.0687

 

  • MktCap 7799466416.0
  • FreeCF/Share 11.7702
  • PFCF 13.4823
  • PE -112.5191
  • Debt/Assets 0.3685
  • DivYield 0
  • ROE -0.0201

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Upgrade CRL Citigroup Neutral Buy -- $200 July 9, 2025
Upgrade CRL Redburn Atlantic Neutral Buy -- $182 May 23, 2025
Upgrade CRL TD Cowen Hold Buy -- $179 May 14, 2025
Upgrade CRL Evercore ISI In-line Outperform -- $170 May 8, 2025
Downgrade CRL Goldman Buy Neutral $190 $170 March 21, 2025
Upgrade CRL Citigroup Sell Neutral $155 $175 March 4, 2025
Upgrade CRL Redburn Atlantic Sell Neutral -- $188 March 3, 2025
Downgrade CRL William Blair Outperform Market Perform -- -- Jan. 22, 2025
Downgrade CRL UBS Buy Neutral $250 $185 Jan. 17, 2025
Initiation CRL CLSA -- Underperform -- $167 Oct. 23, 2024

News

Interpreting Charles River (CRL) International Revenue Trends
CRL
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative

Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.

Read More
image for news Interpreting Charles River (CRL) International Revenue Trends
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
CRL
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral

Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.

Read More
image for news Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
Charles River: Margin Fears Outweigh Solid Q2
CRL
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative

Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.

Read More
image for news Charles River: Margin Fears Outweigh Solid Q2
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
CRL
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Read More
image for news Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
CRL
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.

Read More
image for news CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
CRL
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.

Read More
image for news Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
CRL
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive

CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.

Read More
image for news Charles River Q2 Earnings Preview: What's in Store for the Stock?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
CRL
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
CRL
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative

CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.

Read More
image for news Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
CRL
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Negative

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
Charles River Stock May Gain From Extended CHDI Research Deal on HD
CRL
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Read More
image for news Charles River Stock May Gain From Extended CHDI Research Deal on HD
Charles River Laboratories to Present at William Blair and Jefferies Conferences
CRL
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.

Read More
image for news Charles River Laboratories to Present at William Blair and Jefferies Conferences
Should You Continue to Hold Charles River Stock in Your Portfolio?
CRL
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive

CRL stays on investors' radars due to the strength of partnerships and segmental prospects.

Read More
image for news Should You Continue to Hold Charles River Stock in Your Portfolio?
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
CRL
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral

The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.

Read More
image for news S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
CRL
Published: May 07, 2025 by: Seeking Alpha
Sentiment: Neutral

Charles River Laboratories International, Inc. (NYSE:CRL ) Q1 2025 Results Conference Call May 7, 2025 9:00 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Max Smock - William Blair Eric Coldwell - Baird Elizabeth Anderson - Evercore ISI Ann Hynes - Mizuho Securities Dave Windley - Jefferies Michael Ryskin - Bank of America Justin Bowers - Deutsche Bank Kyle Crews - UBS Patrick Donnelly - Citi Casey Woodring - JPMorgan Charles Rhyee - TD Cowen …

Read More
image for news Charles River Laboratories International, Inc. (CRL) Q1 2025 Earnings Call Transcript
Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
CRL
Published: May 07, 2025 by: Benzinga
Sentiment: Positive

Charles River Laboratories International Inc CRL stock is trading higher on Wednesday after the company released better than expected first-quarter 2025 earnings.

Read More
image for news Charles River Laboratories' Q1 Earnings Beat Consensus, Stock Trades Higher On Signs Of Demand Stabilization
Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
CRL, DIS, SMCI
Published: May 07, 2025 by: Investopedia
Sentiment: Positive

U.S. equities were little changed at midday as the market awaited the Federal Reserve's interest-rate decision coming this afternoon. The Dow Jones Industrial Average was higher, the Nasdaq was lower, and the S&P 500 was basically flat.

Read More
image for news Top Stock Moves Now: Charles River Labs, Disney, Supermicro, and More
Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
CRL
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Read More
image for news Compared to Estimates, Charles River (CRL) Q1 Earnings: A Look at Key Metrics
CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
CRL
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River delivers better-than-expected earnings and revenues in the first quarter of 2025.

Read More
image for news CRL Q1 Earnings & Revenues Beat Estimates, Stock Rises, '25 View Up
Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
CRL
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River Laboratories (CRL) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.06 per share. This compares to earnings of $2.27 per share a year ago.

Read More
image for news Charles River Laboratories (CRL) Beats Q1 Earnings and Revenue Estimates
Charles River Laboratories Announces First-Quarter 2025 Results
CRL
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces First-Quarter 2025 Financial Results.

Read More
image for news Charles River Laboratories Announces First-Quarter 2025 Results
Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
CRL
Published: May 07, 2025 by: Business Wire
Sentiment: Neutral

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value.

Read More
image for news Charles River Laboratories Announces Governance Updates and Strategic Review to Enhance Long-Term Stockholder Value
Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
CRL
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Negative

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Read More
image for news Analysts Estimate Charles River Laboratories (CRL) to Report a Decline in Earnings: What to Look Out for
Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
CRL
Published: April 22, 2025 by: Business Wire
Sentiment: Neutral

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs.

Read More
image for news Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development
Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
CRL
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River (CRL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Read More
image for news Strength Seen in Charles River (CRL): Can Its 6.9% Jump Turn into More Strength?
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
CERT, CRL, SLP
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral

The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.

Read More
image for news What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
CRL
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Read More
image for news Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
CRL
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive

Charles River (CRL) reported earnings 30 days ago. What's next for the stock?

Read More
image for news Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
CRL
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral

Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey …

Read More
image for news Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript

About Charles River Laboratories International, Inc. (CRL)

  • IPO Date 2000-06-23
  • Website https://www.criver.com
  • Industry Medical - Diagnostics & Research
  • CEO James C. Foster
  • Employees 18700

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.